Skip to main content
EJNMMI Research
Fig. 5 | EJNMMI Research

Fig. 5

From: A preliminary clinical trial to evaluate 64Cu-NOTA-Trastuzumab as a positron emission tomography imaging agent in patients with breast cancer

Fig. 5

64Cu-NOTA-Trastuzumab PET images of HER2-positive breast cancer (arrowheads, lower row) and metastatic lymph node (arrows, upper row). The primary tumor and metastatic lymph nodes were clearly observed by 18F-FDG PET/CT (a) and 64Cu-NOTA-Trastuzumab PET/CT (b–d). In HER2-expressing lesions, the uptakes of NOTA increased over time to 48 h after injection

Back to article page